Blueprint Medicines Corporation (0HOJ.L)
USD 82.77
(2.95%)
USD 82.77
(2.95%)
| Year | Net Income | Net Income Growth |
|---|---|---|
| 2023 | -506.98 Million USD | 9.06% |
| 2022 | -557.51 Million USD | 13.44% |
| 2021 | -644.08 Million USD | -305.2% |
| 2020 | 313.88 Million USD | 195.49% |
| 2019 | -328.7 Million USD | -38.9% |
| 2018 | -236.64 Million USD | -59.76% |
| 2017 | -148.11 Million USD | -104.32% |
| 2016 | -72.49 Million USD | -37.38% |
| 2015 | -52.76 Million USD | -30.99% |
| 2014 | -40.28 Million USD | -92.64% |
| 2013 | -20.91 Million USD | 0.0% |
| Year | Net Income | Net Income Growth |
|---|---|---|
| 2024 Q3 | -56.27 Million USD | -12.57% |
| 2024 Q1 | 89.13 Million USD | 180.36% |
| 2024 Q2 | -49.99 Million USD | -156.09% |
| 2023 Q4 | -110.91 Million USD | 17.05% |
| 2023 FY | -506.98 Million USD | 9.06% |
| 2023 Q1 | -129.56 Million USD | 18.33% |
| 2023 Q2 | -132.79 Million USD | -2.5% |
| 2023 Q3 | -133.71 Million USD | -0.69% |
| 2022 Q1 | -105.99 Million USD | 66.74% |
| 2022 FY | -557.51 Million USD | 13.44% |
| 2022 Q2 | -159.7 Million USD | -50.67% |
| 2022 Q4 | -158.63 Million USD | -19.13% |
| 2022 Q3 | -133.16 Million USD | 16.62% |
| 2021 Q4 | -318.68 Million USD | -171.82% |
| 2021 Q1 | -99.71 Million USD | -16.39% |
| 2021 Q2 | -108.44 Million USD | -8.76% |
| 2021 Q3 | -117.24 Million USD | -8.11% |
| 2021 FY | -644.08 Million USD | -305.2% |
| 2020 FY | 313.88 Million USD | 195.49% |
| 2020 Q4 | -85.66 Million USD | -113.51% |
| 2020 Q3 | 633.97 Million USD | 613.45% |
| 2020 Q2 | -123.47 Million USD | -11.28% |
| 2020 Q1 | -110.95 Million USD | -67.27% |
| 2019 Q2 | -99.68 Million USD | -14.04% |
| 2019 Q3 | -94.27 Million USD | 5.42% |
| 2019 Q4 | -66.33 Million USD | 29.64% |
| 2019 FY | -328.7 Million USD | -38.9% |
| 2019 Q1 | -87.4 Million USD | -8.82% |
| 2018 Q1 | -56.54 Million USD | -15.34% |
| 2018 Q2 | -27.04 Million USD | 52.17% |
| 2018 Q3 | -72.72 Million USD | -168.87% |
| 2018 Q4 | -80.32 Million USD | -10.45% |
| 2018 FY | -236.64 Million USD | -59.76% |
| 2017 Q3 | -37.7 Million USD | -12.84% |
| 2017 Q2 | -33.41 Million USD | -19.43% |
| 2017 Q1 | -27.97 Million USD | -31.58% |
| 2017 FY | -148.11 Million USD | -104.32% |
| 2017 Q4 | -49.02 Million USD | -30.03% |
| 2016 Q4 | -21.26 Million USD | -26.31% |
| 2016 Q3 | -16.83 Million USD | 10.9% |
| 2016 Q2 | -18.89 Million USD | -21.87% |
| 2016 FY | -72.49 Million USD | -37.38% |
| 2016 Q1 | -15.5 Million USD | 0.46% |
| 2015 Q3 | -12.64 Million USD | 2.6% |
| 2015 FY | -52.76 Million USD | -30.99% |
| 2015 Q2 | -12.98 Million USD | -12.17% |
| 2015 Q4 | -15.57 Million USD | -23.2% |
| 2015 Q1 | -11.57 Million USD | 20.02% |
| 2014 FY | -40.28 Million USD | -92.64% |
| 2014 Q1 | -7.02 Million USD | 0.0% |
| 2014 Q3 | -10.5 Million USD | -26.74% |
| 2014 Q4 | -14.46 Million USD | -37.75% |
| 2014 Q2 | -8.28 Million USD | -17.93% |
| 2013 FY | -20.91 Million USD | 0.0% |
| Name | Net Income | Net Income Difference |
|---|---|---|
| Thermo Fisher Scientific Inc. | 5.99 Billion USD | 108.457% |
| Dynavax Technologies Corporation | -6.38 Million USD | -7835.264% |
| Illumina, Inc. | -1.16 Billion USD | 56.332% |
| IQVIA Holdings Inc. | 1.35 Billion USD | 137.333% |
| Biogen Inc. | 1.16 Billion USD | 143.664% |
| Iovance Biotherapeutics, Inc. | -444.03 Million USD | -14.176% |
| Mettler-Toledo International Inc. | 788.77 Million USD | 164.275% |
| Sarepta Therapeutics, Inc. | -535.97 Million USD | 5.409% |
| Supernus Pharmaceuticals, Inc. | 1.31 Million USD | 38624.62% |
| Waters Corporation | 642.23 Million USD | 178.941% |
| Perrigo Company plc | -12.7 Million USD | -3892.0% |
| uniQure N.V. | -308.47 Million USD | -64.35% |
| Agios Pharmaceuticals, Inc. | -352.08 Million USD | -43.994% |
| Amicus Therapeutics, Inc. | -151.58 Million USD | -234.457% |
| Atara Biotherapeutics, Inc. | -276.12 Million USD | -83.606% |
| bluebird bio, Inc. | -211.91 Million USD | -139.242% |
| Cara Therapeutics, Inc. | -118.51 Million USD | -327.788% |
| Imunon, Inc. | -19.51 Million USD | -2497.923% |
| Myriad Genetics, Inc. | -112 Million USD | -352.664% |
| Neurocrine Biosciences, Inc. | 249.7 Million USD | 303.037% |
| Nektar Therapeutics | -276.05 Million USD | -83.653% |
| Editas Medicine, Inc. | -153.21 Million USD | -230.888% |
| Verastem, Inc. | -87.36 Million USD | -480.292% |
| Walgreens Boots Alliance, Inc. | -8.63 Billion USD | 94.129% |
| Corbus Pharmaceuticals Holdings, Inc. | -44.6 Million USD | -1036.651% |
| Heron Therapeutics, Inc. | -110.55 Million USD | -358.564% |
| Unity Biotechnology, Inc. | -39.86 Million USD | -1171.912% |
| BioMarin Pharmaceutical Inc. | 167.64 Million USD | 402.415% |
| Sangamo Therapeutics, Inc. | -257.83 Million USD | -96.634% |
| Evolus, Inc. | -61.68 Million USD | -721.892% |
| Adicet Bio, Inc. | -142.65 Million USD | -255.384% |
| Aclaris Therapeutics, Inc. | -88.48 Million USD | -472.986% |
| Regeneron Pharmaceuticals, Inc. | 3.95 Billion USD | 112.823% |
| Esperion Therapeutics, Inc. | -209.24 Million USD | -142.289% |
| FibroGen, Inc. | -284.23 Million USD | -78.37% |
| Agilent Technologies, Inc. | 1.24 Billion USD | 140.886% |
| OPKO Health, Inc. | -188.86 Million USD | -168.44% |
| Homology Medicines, Inc. | -53.74 Million USD | -843.349% |
| Geron Corporation | -184.12 Million USD | -175.345% |
| Alnylam Pharmaceuticals, Inc. | -440.24 Million USD | -15.16% |
| Exelixis, Inc. | 207.76 Million USD | 344.018% |
| Viking Therapeutics, Inc. | -85.89 Million USD | -490.237% |
| Anavex Life Sciences Corp. | -47.5 Million USD | -967.222% |
| Intellia Therapeutics, Inc. | -481.19 Million USD | -5.36% |
| Zoetis Inc. | 2.34 Billion USD | 121.629% |
| Axsome Therapeutics, Inc. | -239.23 Million USD | -111.916% |
| Abeona Therapeutics Inc. | -54.18 Million USD | -835.602% |
| Vertex Pharmaceuticals Incorporated | 3.61 Billion USD | 114.007% |
| Kala Pharmaceuticals, Inc. | -42.19 Million USD | -1101.412% |
| Ionis Pharmaceuticals, Inc. | -366.28 Million USD | -38.412% |
| Corcept Therapeutics Incorporated | 106.14 Million USD | 577.656% |
| Halozyme Therapeutics, Inc. | 281.59 Million USD | 280.041% |
| Insmed Incorporated | -749.56 Million USD | 32.363% |
| TG Therapeutics, Inc. | 12.67 Million USD | 4100.821% |
| Incyte Corporation | 597.59 Million USD | 184.837% |
| Emergent BioSolutions Inc. | -760.5 Million USD | 33.335% |